Johnson & Johnson : to Participate in the Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference
January 27, 2021 at 02:48 pm
Share
New Brunswick, NJ (January 27, 2021) -- Johnson & Johnson (NYSE: JNJ) will participate in the Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on Thursday, February 25th. Jennifer Taubert, Executive Vice President, Worldwide Chairman Pharmaceuticals will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time).
This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.
A webcast and podcast replay will be available approximately 48 hours after the live webcast.
###
Press Contacts:
Christina Chan
(732) 524-6297
Investor Contacts:
Jennifer McIntyre
(732) 524-3922
Attachments
Original document
Permalink
Disclaimer
Johnson & Johnson published this content on 27 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 January 2021 14:47:02 UTC
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).